NMS-E628 is an inhibitor of ALK anaplastic lymphoma kinase (ALK) and Ros1 and an antagonist at Trk receptors; it exhibits anticancer chemotherapeutic activity. Clinically, this compound suppresses tumor growth in non-small cell lung cancer (NSCLC) subjects with NTRK1 gene rearrangements.
| Cas No. | 1108743-60-7 |
|---|---|
| Purity | ≥98% |
| Formula | C31H34F2N6O2 |
| Formula Wt. | 560.64 |
| IUPAC Name | N-[5-(3,5-Difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide |
| Synonym | Entrectinib, RXDX-101 |
| Solubility | DMSO,100mg/mL Ethanol,100mg/mL Water,<1mg/mL |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Amatu A, Somaschini A, Cerea G, et al. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br J Cancer. 2015 Dec 3. [Epub ahead of print]. PMID: 26633560.
Farago AF, Le LP, Zheng Z, et al. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2015 Nov 12. [Epub ahead of print]. PMID: 26565381.
Rolfo C, Ruiz R, Giovannetti E, et al. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs. 2015 Nov;24(11):1493-500. PMID: 26457764.
